Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
One lightly wounded after Iranian missile barrage targets northern Israel - 2US FDA declines to approve Corcept's drug for rare hormonal disorder
- 3Two UN peacekeepers killed in explosion in Lebanon
- 47 Fun Plans to Make Film Evenings Seriously Invigorating (You'll Cherish #5!)
- 5NASA to bring astronauts home from space station early due to a medical issue
- Brazilian cardinal orders a popular Catholic priest to go offline following right-wing attacks
- 'Tangled' live-action movie casts Teagan Croft and Milo Manheim as Rapunzel and Flynn
- Dwayne ‘the Rock’ Johnson opens up about being the 'new guy' again — and why this moment feels like a new life
- 'Stranger Things' Season 5: When does Volume 2 come out? And Volume 3? Everything to know about the remaining episodes before the finale.
- First Alert: Light snow through this evening
- Find Successful Magnificence Items for Sparkling Skin
- IDF, police arrest eleven for criminal, terror-related activity over weekend
- Carina Nebula shines with white-blue stars | Space photo of the day for Jan. 5, 2026
- Monetary Freedom Guide: Plan Your Future
